The copyright and Pharma: A Precarious Bet?

The history of the erectile dysfunction drug presents a complex picture for shareholders. While the initial launch generated substantial returns, the expiration of its patent opened the door to off-brand alternatives, dramatically diminishing sales. This presents a particular challenge for firms

read more